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Abstract
Introduction: Monocytes/macrophages accumulate in the rheumatoid (RA) synovium where they play a central
role in inflammation and joint destruction. Identification of molecules involved in their accumulation and
differentiation is important to inform therapeutic strategies. This study investigated the expression and function of
chemokine receptor CCR9 in the peripheral blood (PB) and synovium of RA, non-RA patients and healthy
volunteers.
Methods: CCR9 expression on PB monocytes/macrophages was analysed by flow cytometry and in synovium by
immunofluorescence. Chemokine receptor CCR9 mRNA expression was examined in RA and non-RA synovium,
monocytes/macrophages from PB and synovial fluid (SF) of RA patients and PB of healthy donors using the reverse
transcription polymerase chain reaction (RT-PCR). Monocyte differentiation and chemotaxis to chemokine ligand 25
(CCL25)/TECK were used to study CCR9 function.
Results: CCR9 was expressed by PB monocytes/macrophages in RA and healthy donors, and increased in RA. In RA
and non-RA synovia, CCR9 co-localised with cluster of differentiation 14+ (CD14+) and cluster of differentiation 68+
(CD68+) macrophages, and was more abundant in RA synovium. CCR9 mRNA was detected in the synovia of all
RA patients and in some non-RA controls, and monocytes/macrophages from PB and SF of RA and healthy
controls. CCL25 was detected in RA and non-RA synovia where it co-localised with CD14+ and CD68+ cells.
Tumour necrosis factor alpha (TNFa) increased CCR9 expression on human acute monocytic leukemia cell line THP-
1 monocytic cells. CCL25 induced a stronger monocyte differentiation in RA compared to healthy donors. CCL25
induced significant chemotaxis of PB monocytes but not consistently among individuals.
Conclusions: CCR9 expression by monocytes is increased in RA. CCL25 may be involved in the differentiation of
monocytes to macrophages particularly in RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease resulting in the accumulation of macrophages,
T cells and B cells within the synovium. The accumula-
tion of these cells is involved in the development of
inflammation, joint destruction and pain [1]. Monocytes
migrate from the blood across the walls of synovial blood
vessels and differentiate into macrophages. The clinical
importance of monocytes/macrophages is revealed by the
correlation between their number, disease activity and
radiographic progression [2-4] and by the beneficial effect
of therapies that target these cells (such as gold salts [5],
methotrexate [6]) and monocyte depletion [7,8]. Further-
more, monocytes/macrophages are a major source of
TNFa in the RA joint and blocking this cytokine has had
a major impact on RA therapy [9,10].
Leukocyte recruitment is dependent on a cascade of
events mediated by chemokines, chemokine receptors
and adhesion molecules [11,12]. The homing, recruiting,
organising and retaining activities of chemokines is
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mokine receptors on the leukocyte surface. In vitro and
in vivo experiments have suggested that disrupting this
interaction could potentially reduce inflammation and
therefore offer a potential therapeutic approach [11].
Evidence has accumulated to show that chemokine
receptors and their ligands are involved in the migration
and retention of leukocytes in the RA joint [13,14]. For
example CCR1, 2, 3 and 5 and CXCR4 are suggested to
be involved for monocytes and CCR5, CXCR3 and
CXCR4 for T lymphocytes.
CCR9 is reported as a receptor on lymphoid cells and
is expressed both constitutively and in inflammation. It
occurs on T lymphocytes of the small intestine, thymus,
lymph node and spleen [15-17]. CCR9 is involved in
T cell homing to the small intestine [15], T cell develop-
ment and migration in the thymus [15,18,19], and
recruitment of T cells in chronic inflammatory disease
[20], being a target in inflammatory bowel disease.
Finally it has been suggested that CCR9 is implicated in
the survival or proliferation of T cell acute lymphoblas-
tic leukemia cells [21]. Therefore CCR9 has mainly been
reported to function in lymphocyte migration although
other cell types, such as tumour cells, can express
CCR9, playing a role in prostate cancer cell migration
and invasion [22].
Contrary to many other chemokine receptors CCR9
binds only one known ligand, CCL25/TECK. This che-
mokine was originally defined as being chemotactic for
activated, but not resting, human monocytic cells and
activated mouse peritoneal macrophages [23]. This
implies the existence of CCR9 on activated monocytes
and macrophages; however, there has been a lack of stu-
dies of CCR9 on these cells in humans and mice. Mono-
cyte/macrophage activation and differentiation play an
important role in RA pathogenesis and their recruitment
to RA joints is a central feature of the disease. Therefore
we examined the expression and function of CCR9 by
monocytes and macrophages in RA.
Materials and methods
Patient and control samples
RA patients (n = 24) were aged 33 to 91 (19 female,
5 male), had disease duration of 1 to 42 years, active
disease defined by elevated ESR and CRP, positive rheu-
matoid factor (apart from three patients), and took
disease-modifying drugs (etanercept, methotrexate, leflu-
nomide or hydroxychloroquine) or steroids. The non-
RA subjects (n = 7) were aged 42 to 60 years (six male,
one female), had no history of RA and were medication-
free [24]. Normal healthy volunteers (n =2 0 )w e r ea g e d
24 to 63 (11 female, 9 male), had no joint symptoms
and were medication-free.
The synovial samples were obtained from RA and
non-RA patients following total knee replacement and
arthroscopy respectively. RA synovia showed classic
synovitis with lymphocyte and macrophage infiltration
of the sublining, and lining layer thickening (as pre-
viously described [24,25]); with little or no fibrosis.
Non-RA synovia were from knees with suspected menis-
cal or cartilage damage. Biopsies were from arthroscopi-
cally non-inflamed sites and subsequent histology
showed they were essentially normal with no post-trau-
matic synovitis [24,25].
RA patients included in this study fulfilled the Ameri-
can Rheumatism Association criteria for RA. All samples
were taken with informed consent and ethical approval.
Flow cytometry
RA peripheral blood (PB) and matching synovial fluid
(SF) and healthy PB were collected into preservative-free
heparin. SF was treated with hyaluronidase for 30 min-
utes at 37°C. PB and SF mononuclear cells were isolated
by gradient centrifugation with Ficoll-Paque Plus (Amer-
sham-Biosciences, Little Chalfont, UK). Analysis of che-
mokine receptor surface expression was performed
using three-colour immunofluorescence, as previously
described [26]. After blocking non-specific binding with
10% IV-Ig (Flebogamma, Grifols, Cambridge, UK Ltd),
PB and SF mononuclear cells (3 × 10
5)w e r es t a i n e d
with anti-chemokine receptor antibody or isotype con-
trol, followed by FITC-labelled secondary antibodies
(Cambridge Biosciences, Cambridge, UK). After blocking
non-specific binding sites with mouse serum, cells were
further stained with directly conjugated CD14-PECy5
and CD16-PE antibodies. The samples were analysed on
an EPICS XL flow cytometer (Beckman Coulter, High
Wycombe, UK). Cytometer calibration was standardized
using fluorospheres (Flow-Set, Coulter). Data were ana-
lysed using WinMDI version 2.8 (The Scripps Institute,
La Jolla, CA, USA).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA extraction and RT-PCR was as our pre-
vious study [24] except that specific primers (MWG
Biotech, Ebersberg, Germany) for CCR9 (product size
572 bp, [Genbank:NM_031200]), CCL25 (product size
311 bp, [GenBank:NM_005624]) and L27 (product size
344 bp, [GenBank:BC007273]) were used. The RT-PCR
conditions were one cycle at (94°C for three minutes,
57°C for one minute, 72°C for one minute), X cycles at
(94°C for one minute, 57°C for one minute, 72°C for
one minute) and one cycle at (94°C for one minute,
57°C for one minute, 72°C for 10 minutes). X equals
34 cycles for CCR9, 35 cycles for CCL25 and 24 cycles
for L27.
Schmutz et al. Arthritis Research & Therapy 2010, 12:R161
http://arthritis-research.com/content/12/4/R161
Page 2 of 12Immunohistology
Immunohistochemistry using paraffin embedded sections
were as [24] except that antigen demasking was for 15
minutes microwaving in citrate buffer (pH 6.0). H2O2
treatment was not necessary. Non-specific sites were
blocked with normal horse serum (in phosphate buffered
saline (PBS)) for 10 minutes before applying anti-human
CCR9 goat polyclonal antibody (1:250, Capralogics,
Hardwick, MA, USA) and the respective IgG control
(Dako, Ely, UK). Antibody detection was by the Vectas-
tain ABC Elite kit (Vector, Peterborough, UK) and 3,3′-
diaminobenzidine (DAB) (Vector). Sections were rinsed
and counter stained in Mayer’s haematoxylin.
For double label immunofluorescence, cryosections
(6 μm thick) were fixed in acetone for 10 minutes on
ice, rinsed with PBS and incubated for one hour with
CCR9 goat polyclonal antibody (as above 1:250) together
with antibodies to either CD14 (1:20), CD68 (1:50),
CD20 (1:100) or CD3 (1:50) (all from Dako, Ely, UK).
Detection of CCR9 was with donkey anti-goat Alexa 594
and the other primary antibodies with goat anti-mouse
Alexa 488 secondary antibodies, containing 10% human
serum. For CCL25 the slides were incubated with anti-
human CCL25 mouse monoclonal antibody (1:200, R&D
Systems, Abingdon, UK) together with anti-CD14 or
-CD68. CCL25 was then detected with isotype specific
goat anti-mouse IgG2b Alexa 488, and CD68 and CD14
were detected with goat anti-mouse IgG1 and IgG2a
Alexa 594 second antibodies respectively. Finally nuclear
staining was performed with DAPI for three minutes,
before mounting.
Controls were using species- or isotype-matched IgGs
(Dako) instead of primary antibodies followed by the
respective Alexa-labelled secondary antibodies.
Stimulation of THP-1 cells with TNFa
THP-1 cells were grown in RPMI medium with 10%
FBS and treated with TNFa (0 to 500 ng/ml) (Pepro-
Tech, London, UK) for 16 hours. They were then incu-
bated with anti-CCR9 mouse monoclonal antibody
(1:10; R&D Systems) followed by goat anti-mouse
IgG2a-RPE conjugate (1:100, Southern Biotech, Birming-
ham, AL, USA) and analysed with a Becton Dickinson
FACSCAN.
Monocyte differentiation
PB was taken and erythrocytes eliminated using lysing
buffer. Leukocytes (3 × 10
5 cells/well) were treated with
hrCCL25 (0 to 500 ng/ml) (Peprotech UK), hrCXCL16
(0 to 500 ng/ml) (Peprotech, UK) or phorbal myristate
acetate (PMA) (10 ng/ml; Sigma, Poole, UK) in RPMI
containing 10% heat inactivated FBS for three hours at
37°C. They were incubated with CD14PE (1:50 in PBS
with 5% FBS; BD Biosciences, Oxford, UK) and CD36-
FITC antibodies (1:250 in PBS with 5% FBS; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 30 minutes
(4°C). Monocyte populations were gated using FSC/SSC
and anti-CD14PE, and CD36 MFI determined using a
BD FACS Canto Flow Cytometer.
From two of the RA and healthy subjects, PB mono-
cytes were also isolated using CD14+ positive selection
using MACS microbeads (Miltenyi Biotec, Bisley, UK)
and treated as above. The stimulatory effects of CCL25
on CD36 expression were significant and similar to
those obtained using the erythrocyte lysis method of
leukocyte isolation (described above).
Chemotaxis assay
PB monocytes were isolated by positive selection using
CD14+ MACS microbeads (Miltenyi Biotec) according
to the manufacturer’s instructions. The migration of the
CD14+ cells was assayed in Transwell (Corning Incor-
porated Costar, Cambridge, MA, USA) with 5 μmp o r e
size filter. The bottom of the well was siliconised (Sig-
macote, Sigma, UK) to prevent cell adhesion. Medium
containing 0.5% FractionV BSA and 0 to 1,000 ng/ml of
CCL25 or 100 ng/ml MCP-1 was added to the bottom
chamber, the filters were dropped in the medium and
0.5 × 10
6 cells were immediately added. The transwells
w e r ei n c u b a t e da t3 7 ° Cf o ro n eh o u ra n df i n a l l yt h e
cells in the upper and lower compartment were col-
lected, stained with CD14 and CD16, and analysed by
flow cytometry using an EPICS XL flow cytometer (as
described above for flow cytometry).
Statistics
T-tests were used to compare CCR9 expression by RA
and normal monocytes using flow cytometry (signifi-
cance level <0.05). The effect of TNFa concentrations
on CCR9 expression was determined by ANOVA and
then pair-wise comparisons by Dunnett’s test. The influ-
ence of CCL25 and PMA on CD36 expression was ana-
lysed using multilevel or hierarchical regression analysis
on log transformed data, using the ratio test to compare
the various multilevel models and the Wald test to
obtain P-values [27,28].
For quantitation of the number of CCR9/CD14 posi-
tive cells by immunofluorescence microscopy, five fields
of view of the synovial sublining at ×600 magnification
were examined per patient and the number of CCR9+,
CD14+ and CCR9+/CD14+ cells counted. Thus the
mean numbers of positive cells (± standard error) per
field of view were obtained; the total number of cells
sampled per field of view was assessed by counting the
numbers of nuclei stained by DAPI. T tests were used
to compare RA and non-RA data.
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CCR9 expression by PB monocytes
CCR9 expression by monocytes was examined from RA
PB and healthy PB using flow cytometry. The total
monocyte population and two subpopulations were
defined according to their FSC/SSC characteristics and
surface marker expression with total monocytes all
being CD14+, and the two subpopulations being CD14+
and CD16- or CD14+ and CD16+. In accordance with
previous results [29] the CD14+/CD16- and CD14
+/CD16+ subpopulations were both present in all RA
(n = 7) and healthy (n = 6) PB samples, however marked
heterogeneity was observed in the RA SF, with these two
CD14/CD16 subpopulations being observed together in
only one out of seven SF samples analysed (data not
shown).
CCR9 was consistently observed in the CD14+ mono-
cyte population and in the two subpopulations in both
RA and healthy samples, examples of RA CCR9 and iso-
type control plots are shown in Figure 1a. CCR9 was
significantly more abundant in RA PB than in normal
PB in the CD14+ population and the CD14+/CD16-
subpopulation (mean fluorescence intensity (MFI), P <
0.05) (Figure 1b). No significant difference was observed
between the RA and normal CD14+/CD16+
subpopulation.
To determine if the number of CCR9 positive cells
also varied between RA and healthy samples the percen-
tage of CCR9+ monocytes was determined for the total
CD14+ population. There were significantly more CCR9
positive CD14 monocytes in RA PB than normal PB
(P < 0.05) above background (isotype control IgG2a)
(Figure 1c).
The levels of CCR9 on CD14+ monocytes in the same
RA PB and healthy PB samples were compared with
other chemokine receptors. For RA PB the MFI (mean
± SD) for CCR1, CCR2, CCR5 and CXCR4 was 46 ± 13,
92 ± 20, 14 ± 10 and 17 ± 6, and for healthy PB 41 ±
17, 94 ± 40, 10 ± 4 and 11 ± 8 respectively. For RA PB
the percentage positive cells (mean ± SD) for CCR1,
CCR2, CCR5 and CXCR4 was 94 ± 10, 94 ± 8, 55 ± 31,
72 ± 13, and for healthy PB 99 ± 1, 99 ± 1, 58 ± 22 and
46 ± 26 respectively.
CCR9 expression in synovium
CCR9 expression was examined by immunohistochemis-
try on paraffin embedded synovial sections. The recep-
tor was detected in the synovia of all RA and non-RA
patients, occurring on isolated cells in the tissue sublin-
ing at the edge of, or remote from, lymphoid follicles
(data not shown). From their distribution and histologi-
cal shape, these CCR9+ cells were identified as being
potentially macrophages. To investigate this, double
label immunofluorescence was performed on synovial
cryosections using antibodies to CCR9 and markers of
monocytes/macrophages. CCR9 co-localised with CD14
(Figure 2a-c) and CD68 (Figure 2d-f) in RA and non-RA
synovia. This co-localisation occurred in the sublining
using CD14 and CD68 markers and in some regions of
the lining layer with the CD68 marker. No co-localisa-
tion was observed between CCR9 and CD20 (B lympho-
cytes) or CD3 (T lymphocytes) respectively in either RA
or non-RA synovia (data not shown). Non-RA synovial
samples displayed limited staining with CD3 and only
occasional staining with CD20. No staining was detected
using the isotype controls for all antibodies studied.
In order to quantitate differences in CCR9 expression
by macrophages in RA and non-RA synovia, the number
of CCR9+, CD14+ cells and CCR9+/CD14+ cells were
counted in the sublining layer (Table 1). The total num-
ber of CCR9+ cells increased in RA compared to non-
RA ST by approximately five-fold (from 12 to 63 cells
per field of view, P < 0.001). As expected the number of
CD14+ cells in control synovium was low, increasing
12-fold in RA (from 6 to 70 cells per field of view).
Interestingly there was a large increase in the number of
CCR9/CD14 double positive cells in RA compared to
non-RA, amounting to 14-fold (from 4 to 57 cells per
field of view, P < 0.004). The percentage of CD14+
macrophages that were positive for CCR9 was higher in
RA than in non-RA synovia, being 81 and 66% respec-
tively (as calculated by number of CCR9+/CD14+ cells
÷ number of CD14+ cells × 100 in Table 1). In addition,
the vast majority of CCR9+ cells were CD14+ macro-
phages in RA synovium since 90% of these cells were
CD14+ (as calculated by number of CCR9+/CD14+ ÷
CCR9+ cells × 100 in Table 1), whereas this figure was
33% in non-RA synovium.
RT-PCR analysis of CCR9
To support the immunohistology data, mRNA expres-
sion was analysed in RA and non-RA synovia. PCR pri-
mers were run through a BLAST program to ensure
gene specificity of the RT-PCR results and to exclude
the possibility of cross-hybridization with other genes.
CCR9 mRNA was present in the synovia of all eight
patients though at a much lower level in Patient 6 (Fig-
ure 3a). CCR9 was also detected in non-RA samples
however only in four out of seven patients. The PCR
reactions were normalised with L27 (L27 ribosomal
gene) to allow for comparison between samples.
To further investigate whether macrophages are them-
selves producing CCR9 and confirm the flow cytometric
results, we performed RT-PCR on monocytes/macro-
phages isolated from PB and SF of four RA patients and
PB of nine healthy volunteers. CCR9 mRNA was
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both PB and SF (Figure 3b). The message for this recep-
tor was also present in PB monocytes/macrophages
from healthy donors (Figure 3c).
CCL25 expression
The expression of CCL25 in the synovium was investi-
gated by immunofluorescence microscopy of cryosec-
tions. CCL25 was expressed in synovia of all RA (n =8 )
and non-RA (n = 5) patients. The chemokine was
observed in cells of the sublining. Double labelling using
antibodies to CD14 or CD68 together with CCL25,
identified CCL25+ cells as being macrophages (Figure
4a-d). No staining was detected in the isotype controls.
Messenger RNA expression was analysed in RA and
non-RA synovia. CCL25 mRNA was present in three
out of eight RA samples (Figure 4e). In non-RA synovia
CCL25 was also detectable however only in one out of
seven samples. The PCR reactions were normalised with
L27 (L27 ribosomal gene). These results indicate that
CCL25 message is detectable in synovia although, unlike
the protein it was not present in every sample. The lack
of exact correlation between mRNA and protein has
been shown for other genes [25] and suggests that
Figure 1 CCR9 expression by monocytes in RA using flow cytometry. (a) Representative histograms showing CCR9 expression by the total
CD14+ population, and two subpopulations CD14+/CD16- and CD14+/CD16+ (solid fill), empty fill histograms represent the isotype-matched
control used instead of anti-CCR9. (b) Results expressed as MFI (mean fluorescence intensity) showing CCR9 expression by monocytes from
normal and rheumatoid peripheral blood (PB). (c) Results shown as percentage of monocytes expressing CCR9 in the total CD14+ population.
* = significant difference between normal and rheumatoid PB (P < 0.05).
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TNFa-stimulated up-regulation of CCR9 on THP-1 cells
To examine the effects of activation on CCR9 expres-
sion by monocytes, the monocytic cell line THP-1 was
stimulated with TNFa (0 to 500 ng/ml) [23] (Figure 5a).
This cytokine elicited an up-regulation of CCR9 expres-
sion as shown by flow cytometry (P <0 . 0 1 ) .T h e r ew a s
a maximum stimulation at 100 ng/ml (P <0 . 0 1 )a n d
200 ng/ml (P < 0.05) TNFa compared to control.
Functional aspects of monocyte CCR9
To investigate the functionality of CCR9 chemotaxis
experiments were performed. PB monocytes responded
to CCL25 (P < 0.01) with an optimal response at 500
ng/ml (P < 0.01) (Figure 5b). However, chemotactic
responses to CCL25 were not observed in all individuals
despite showing significant responses to CCL2, the clas-
sic monocyte attracting chemokine. Identical results
were obtained for the CD14+CD16- and CD14+CD16+
subpopulations (not shown).
To examine if CCL25 affected the differentiation of
monocytes, its influence on the levels of the scavenger
receptor CD36 was studied. Preliminary experiments
using the monocytic cell line U937 showed that CCL25
(0 to 500 ng/ml) induced differentiation of these cells as
indicated by a concentration dependent increase of
CD36 levels (P < 0.0001) (data not shown).
On RA monocytes CCL25 (0 to 500 ng/ml) gave a sig-
nificant increase in CD36 expression on RA monocytes
(P < 0.001) (Figure 5c). At 50 ng/ml, 100 ng/ml and 500
ng/ml CCL25, CD36 levels were significantly higher
than in the absence of chemokine (P < 0.001). PMA
(positive control) also gave an increase in CD36 expres-
sion (P <0 . 0 0 1 )c o m p a r e dt oc o n t r o l .I nh e a l t h yi n d i v i -
duals CCL25 also stimulated the expression of CD36
(P < 0.001) on monocytes (Figure 5d). There were sig-
nificant increased levels of CD36 at all concentrations
tested compared to the no chemokine control
(P < 0.001 in each case). PMA also gave a significant
stimulation in CD36 levels compared to control
(P < 0.001).
There was no significant difference in CD36 expres-
sion between control RA and healthy monocytes in the
absence of CCL25. However, in the presence of CCL25
RA monocytes were more responsive than healthy
monocytes (Figure 5c, d). This was shown by the rise in
CD36 levels from baseline to 50, 100 and 500 ng/ml
CCL25 being significantly greater for RA than healthy
monocytes (P = 0.007, P <0 . 0 0 1a n dP <0 . 0 0 1r e s p e c -
tively). Furthermore, at 100 ng/ml and 500 ng/ml
CCL25 RA monocytes displayed marked increases in
CD36 expression amounting to 12- and 19-fold respec-
tively compared to no chemokine control, whereas non-
RA monocytes gave only 2- and 3-fold increases respec-
tively. Similarly for PMA stimulation, the rise in CD36
expression was greater on RA than healthy monocytes
(P < 0.001).
CXCR6 was expressed at very low levels on RA and
healthy PB monocytes by flow cytometry (MFI <0.46), in
agreement with others [30]. Addition of CXCL16 (the
ligand for CXCR6) at 50, 100 and 500 ng/ml gave no
significant increase in CD36 levels on RA and healthy
monocytes for each concentration (Figure 5c, d).
CCL25 also stimulated the expression of alternative
macrophage scavenger receptors CD91 and SR-A by RA
and healthy monocytes (data not shown).
Discussion
The results of this study show an increased expression
of CCR9 on circulating monocytes in the blood of
Figure 2 Expression of CCR9 by macrophages in rheumatoid
synovium. Cryosections were treated with antibodies to CCR9 and
CD14 or CD68 as markers of macrophages and double label
immunofluorescence microscopy performed. (a) Shows staining for
CCR9 (red) and (b) shows the same area stained for CD14 (green).
(c) Shows a merge of images (a) and (b) and cells with colocalised
CCR9 and CD14 (yellow). (d, e) Demonstrate staining for CCR9 and
CD68 respectively and (f) is a merge of these two images, cells in
yellow express CCR9 and CD68. Cell nuclei stain (blue) with DAPI in
(c) and (f). The bar represents 50 μm.
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tors per monocytic cell increases but also the percentage
of monocytic cells bearing this receptor increases.
Furthermore, in the synovium there is an increase in the
number and percentage of macrophages that express
CCR9 in RA. The percentage of CCR9+ monocytes in
RA synovium (81%) is greater than that in blood (40%),
similarly in non-RA the percentage of CCR9+ mono-
cytes in the synovium (66%) is increased compared to
that in blood (16%). This suggests there may be a pre-
ferential recruitment of monocytes bearing this receptor
into the synovium or an up-regulation of the receptor,
possibly by cytokines (for example, TNF), once the cells
have migrated into the tissue.
Monocytes migrate from the blood into tissues and
differentiate into resident macrophages. This occurs via
sublining blood vessels in the normal and RA synovium.
However, in the latter the number of monocytes
recruited and the accumulation of macrophages is mark-
edly increased. When monocytes differentiate into
macrophages they up-regulate pattern recognition recep-
tors, such as scavenger receptors and toll-like receptors
[31]. Like other scavenger receptors CD36 acts as a pha-
gocytic receptor [32] and was used in the current study
as a marker of monocyte to macrophage differentiation
[33]. In addition CD36 has been detected on macro-
phages in the RA joint [34].
A major finding of the current study was the stimula-
tory effect of CCL25 on monocyte differentiation. The
results show that in RA the basal CD36 levels on mono-
cytes are similar to those of normal monocytes.
However, upon CCL25 stimulation RA monocytes are
significantly more responsive in terms of CD36 expres-
sion. This increased responsiveness may be related to
the increased abundance of CCR9 found on RA blood
monocytes, as shown by the MFI flow cytometry data.
In addition, the increased responsiveness was not only
CCL25-related since PMA, a known inducer of mono-
cyte differentiation [35], also elicited a greater response
in RA monocytes compared to normal. CCL25 appears
to function like CXCL4 which is another chemokine
reported to stimulate the differentiation of monocytes to
macrophages [36]. It is unknown, as yet, whether CCR9
is modulated during monocyte differentiation and differ-
entially expressed by polarized (M1 and M2) macro-
phages, together with the effect of CCL25 on markers of
macrophage polarization.
CCL25 was originally defined as being chemotactic for
activated, but not resting, human monocytic THP-1
cells, and activated mouse peritoneal macrophages [23].
This implies the existence of CCR9 on activated mono-
cytes and macrophages, although this was not formally
shown experimentally. In order to further this study of
Vicari et al. [23], we showed that activation of THP-1
cells with TNFa results in increased CCR9 expression.
In RA, monocytes in the circulation show evidence of
increased activation prior to their entry into the syno-
vium, as well as in the synovium itself [10]. Therefore
the increase in the expression of CCR9 may be related
to the enhanced activation state of monocytes/macro-
phages in the RA circulation and synovial tissue. The
mechanism behind the up-regulation of CCR9 on
Table 1 The number of double positive CCR9/CD14 cells in rheumatoid and non-rheumatoid synovial tissue
Patient Number of CCR9+ cells
(mean ± SE)
Number of CD14+ cells
(mean ± SE)
Number of CCR9+/CD14+ cells
(mean ± SE)
Rheumatoid
1( n = 92) 25 ±10 36 ± 9 25 ± 10
2( n = 91) 59 ± 23 45 ± 25 43 ± 24
3( n = 137) 64 ± 20 64 ± 20 51 ±12
4( n = 136) 60 ± 10 60 ± 13 59 ± 12
5( n = 173) 65 ± 23 80 ± 35 62 ± 24
6( n = 166) 106 ± 9 135 ± 11 104 ± 9
Overall mean ± SE 63 ± 10 70 ± 14 57 ± 11
Non-rheumatoid
1( n = 76) 38 ± 12 1 ± 1 1 ± 1
2( n =7 7 ) 5±5 4±3 3±3
3( n =7 0 ) 9±4 4±6 4±6
4( n =4 7 ) 5±1 5±2 4±3
5( n = 75) 5 ± 3 11 ± 4 5 ± 4
6( n = 75) 10 ± 3 10 ± 2 7 ± 2
Overall mean ± SE 12 ± 5 6 ± 2 4 ± 1
The data are mean numbers of positive cells (± standard error) per field of view; n = mean number of total cells sampled per field of view as assessed by
counting the numbers of nuclei stained by DAPI.
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elevated cytokines, such as TNFa, in the circulation
which occurs in RA [37]. Alternatively the increased
CCR9 expression on monocytes may be due to changes
occurring in the bone marrow which are known to
occur in the disease [38-40].
The level of CCR9 expression on blood monocytes in
RA and healthy patients was compared with other che-
mokine receptors using flow cytometry. In terms of MFI
and the percentage positive cells, CCR9 expression was
similar to CCR5 and CXCR4, although was not as highly
expressed as CCR2 and CCR1.
CCR9 is described as an important chemokine recep-
tor in the gut environment where it is constitutively
expressed in the majority of CD4+ and CD8+ T
lymphocytes of the small intestine [15,17,41,42]. In the
circulation it is also expressed by discrete subsets of
memory CD4+ and CD8+ lymphocytes expressing the
intestinal homing receptor a4b7 [15]. Adoptive transfer
models and in vivo neutralisation experiments have
revealed that CCR9 and CCL25 play important roles in
the localisation of effector T cells to the small intestinal
mucosa [43,44]. In the present study, CCR9 was not
detected in T lymphocytes in the RA and non-RA syno-
vium. This suggests that the CCR9+/a4b7+ subset of
T cells are not recruited to the synovium and other che-
mokine receptors and adhesion molecules are important
for T cell migration into this tissue [17,45]. Further-
more, our data support the notion of a tissue-specific
address code for T cell recruitment to the synovium
Figure 3 CCR9 mRNA in synovial tissue and monocytes/macrophages by RT-PCR. (a) RNA isolated from the synovia of rheumatoid arthritis
patients (n = 8) and controls (n = 7) showing the presence of CCR9 mRNA. (b) CCR9 mRNA expression by monocytes/macrophages isolated
from peripheral blood (PB) and paired synovial fluid (SF) from four RA patients. (c) CCR9 mRNA detected in monocytes/macrophages isolated
from the PB of normal healthy volunteers. L27 was used for normalisation.
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Page 8 of 12that is different from the gut. In inflammatory gut dis-
ease, CCR9+ T cells are more abundant in the PB of
patients with celiac disease or Crohn’s disease [42]. We
observed a similar pattern for monocytes in RA patients.
However, the percentage of CCR9+ T lymphocytes was
shown to be reduced in the small intestine with Crohn’s
disease [42,43,46] whereas in the present study the per-
centage of CCR9+ macrophages in RA ST did not
reduce compared with normal, but was increased.
CCL25 has been shown to be produced by dendritic
and epithelial cells in the normal thymus [23,46,47]. In
addition, in the small intestine CCL25 is constitutively
expressed by epithelial and endothelial cells [17,23,41].
In inflamed small intestine in Crohn’s disease CCL25
expression is in epithelial cells in proximity to lympho-
cytic infiltrates and is not detectable on endothelial cells
[42]. In the present study CCL25 localised to CD14+
and CD68+ cells in the synovial sublining indicating
that macrophages are a source of this chemokine.
Furthermore the production of CCL25 by synovium is
supported by the presence of CCL25 mRNA in RA and
non-RA synovial tissue, although levels were low. Our
results suggest a positive autocrine loop. Macrophages
present in the synovial sublining produce CCL25 leading
Figure 4 CCL25 expression in the rheumatoid synovium. Sections were treated with antibodies to CCL25 and CD68, followed by double
label immunofluorescence microscopy. (a) Shows staining for CD68 (red) in cells of the synovial sublining. (b) Same field of view as A labelled
for CCL25 (green). (c) Shows staining for nuclei using DAPI (blue). (d) Merge of A, B and C showing CD68+CCL25+ cells. Arrows indicate
examples of cells where CD68 and CCL25 colocalise. The bar represents 100 μm. E, CCL25 mRNA in synovial tissue by RT-PCR. RNA isolated from
the synovia of rheumatoid arthritis patients (n = 8) and controls (n = 7) showing the presence of CCL25 mRNA. L27 was used for normalisation.
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Page 9 of 12to the local stimulation of monocyte differentiation to
macrophages. Interestingly CD14+ macrophages are
likely to represent a recently recruited immature subpo-
pulation of macrophages in the synovial sublining, losing
CD14 expression upon maturity [3]. Therefore CCR9 on
these CD14+ cells may play a role in the differentiation
of recently immigrated monocytes. CCL25 was also pre-
sent in non-inflamed control synovia and this chemo-
kine stimulated CD36 up-regulation by monocytes from
normal healthy donors, although less so compared to
RA. Therefore it is possible that CCL25 may enhance
the differentiation of monocytes to macrophages under
constitutive conditions in the non-inflamed synovium.
The effect of CCL25 on monocyte chemotaxis was not
consistent; therefore this chemokine may be more effec-
tive at influencing differentiation rather than monocyte
recruitment.
A very recent in vivo paper by Jacobs et al. [48]
reported the use the K/BxN serum-transfer model of
arthritis in mice. CXCR2 was found to be critical for the
development of autoantibody-mediated arthritis, and
neutrophil recruitment to the joints. This model reflects
Figure 5 Regulation and function of CCR9. (a) Up-regulation of CCR9 on THP-1 monocytic cells by TNFa. Cells were cultured for 16 hours in
the absence or presence of various concentrations of TNFa, then analysed for CCR9 expression by flow cytometry, *P < 0.05 and **P < 0.01
compared to the absence of TNFa. (b) Chemotactic response of peripheral blood monocytes from healthy donors to increasing concentrations
of CCL25, CCL2 (MCP-1) as positive control, from 1 representative healthy donor in duplicate.** = P < 0.01 compared to control. (c, d) CCL25
stimulates CD36 expression by RA (c) and non-RA (d) monocytes. Peripheral blood monocytes were isolated and treated with CCL25, CXCL16 or
PMA for three hours, followed by flow cytometry to detect CD36. Data for CCL25 and PMA are means ± standard errors from five RA and non-
RA individuals all in triplicate. *** = P < 0.0001 compared to control (no CCL25). The rise in CD36 expression in response to CCL25 is greater for
RA (c) than healthy (d) monocytes (P < 0.01 at 50 ng/ml, P < 0.001 at 100 ng/ml and 500 ng/ml CCL25 compared to control). The CXCL16 data
represent two RA and two non-RA individuals in triplicate.
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Page 10 of 12the effector phase of arthritis rather than the initial
adaptive immune response. Other chemokine receptors
such as CCR9, CCR1-7, CXCR3, CXCR5 and CX3CR1
were not critical in the model. Many of these receptors
have been shown to play a role in arthritis using alterna-
tive models that involve an adaptive immune response,
probably functioning at that stage. There have been no
studies targeting CCR9 in these adaptive immune
response models and it would be interesting to perform
such a study. An alternative approach to assess the role
of CCR9 in vivo in RA would be to perform a human
study. There is currently a CCR9 antagonist that shows
promise in clinical trials for Crohn’s disease [49,50], in
fact this is one of the few clinical trials targeting chemo-
kine receptors that show hope in the treatment of
inflammatory diseases. So a clinical study using this
antagonist in human RA would be of interest, also over-
coming problems of lack of exact correlation between
animal models of RA and human disease.
Conclusions
Macrophages are held to be an important cell type
responsible for the pathogenesis of RA [51]. These cells
are major sources of cytokines, such as TNF, chemo-
kines, and degradative enzymes that drive joint inflam-
mation and destruction. Furthermore, it is indicated that
they play a role in angiogenesis and antigen presenta-
tion. The present study shows the presence of CCR9 on
monocytes/macrophges in RA where this receptor sti-
mulates monocyte differentiation. Therefore CCR9 may
be an interesting therapeutic target in RA and suggests
the use of CCR9 antagonists in the disease.
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